Empagliflozin Attenuates Arrhythmias in an iPSC-Based Model of Hypertrophic Cardiomyopathy

Circ Genom Precis Med. 2024 Jun;17(3):e004526. doi: 10.1161/CIRCGEN.123.004526. Epub 2024 May 16.
No abstract available

Keywords: arrhythmias; cardiac; cardiomyopathy; drug repositioning; genetics; hypertrophic; myocytes; sodium-glucose transporter 2 inhibitors.

Publication types

  • Letter

MeSH terms

  • Arrhythmias, Cardiac* / drug therapy
  • Arrhythmias, Cardiac* / pathology
  • Benzhydryl Compounds* / pharmacology
  • Benzhydryl Compounds* / therapeutic use
  • Cardiomyopathy, Hypertrophic* / drug therapy
  • Cardiomyopathy, Hypertrophic* / genetics
  • Cardiomyopathy, Hypertrophic* / pathology
  • Glucosides* / pharmacology
  • Glucosides* / therapeutic use
  • Humans
  • Induced Pluripotent Stem Cells* / cytology
  • Induced Pluripotent Stem Cells* / metabolism
  • Sodium-Glucose Transporter 2 Inhibitors / pharmacology
  • Sodium-Glucose Transporter 2 Inhibitors / therapeutic use

Substances

  • Glucosides
  • Benzhydryl Compounds
  • empagliflozin
  • Sodium-Glucose Transporter 2 Inhibitors